All In Biotech

Drug Trial Radar · NCT02070380

Crossover Comparison of MultiHance and Dotarem

Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain

Last checked: Nov 20, 2026Latest source record: Jan 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Feb 2014

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Lead sponsor
Bracco Diagnostics, IncIndustry
Sponsor type
Industry
First posted
Feb 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.

Conditions

  • Brain Disease

Interventions

  • MultiHance 0.1 mmol/kgDrug

    MultiHance administered at 0.1 mmol/kg

  • DotaremDrug

    Dotarem administered at 0.1 mmol/kg

  • MultiHance 0.05 mmol/kgDrug

    MultiHance administered at 0.05 mmol/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global Diagnostic Preference Between the Two ExamsTime frame: Comparison of image sets obtained within 2 to 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samaritan Health Services

    Corvallis, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.